GeoVax Labs, Inc. (GOVX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update
November 9, 2022 4:00 PM ESTPhase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology
Company Secures Rights to NIH-MVA for Protection Against Monkeypox and Smallpox
ATLANTA, GA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results for the third quarter... More



